These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32110525)

  • 41. Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial.
    Pugh TJ; Choi S; Nogueras-Gonzalaez GM; Nguyen QN; Mahmood U; Frank SJ; Mathai B; Zhu XR; Sahoo N; Gillin M; Kuban DA; Hoffman KE; McGuire SE; Lee AK
    Int J Part Ther; 2016; 3(1):27-36. PubMed ID: 31772973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
    Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
    Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
    Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
    Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.
    Alongi F; Fogliata A; Navarria P; Tozzi A; Mancosu P; Lobefalo F; Reggiori G; Clivio A; Cozzi L; Scorsetti M
    Strahlenther Onkol; 2012 Nov; 188(11):990-6. PubMed ID: 23053143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
    Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
    Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.
    Lopez Guerra JL; Isa N; Matute R; Russo M; Puebla F; Kim MM; Sanchez-Reyes A; Beltran C; Jaen J; Bourgier C; Marsiglia H
    Clin Transl Oncol; 2013 Apr; 15(4):271-7. PubMed ID: 22855189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Image-guided radiation therapy produces lower acute and chronic gastrointestinal and genitourinary toxicity in prostate cancer patients.
    Stuk J; Vanasek J; Odrazka K; Dolezel M; Kolarova I; Hlavka A; Vitkova M; Sinkorova Z
    J BUON; 2021; 26(3):940-948. PubMed ID: 34268957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
    Gottschalk A
    Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
    Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT.
    Guckenberger M; Lawrenz I; Flentje M
    Strahlenther Onkol; 2014 Jan; 190(1):48-53. PubMed ID: 24196279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients.
    Choong ES; Hruby G; Yang J; Kwong C; Patanjali N
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e356-e363. PubMed ID: 27863019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
    Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
    Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.